When should a medical air evacuation of an Ebola patient be considered What are the risks both for the patient and the accompanying medical staff and airplane crew
In July 2012, the European Centre for Disease Prevention and Control initiated a Europe-wide investigation on a Salmonella Stanley outbreak, together with the affected Member States, the European Food Safety Authority (EFSA) and the European Reference Laboratory for Salmonella (EURL Salmonella).
Findings in this study confirmed the herd immunity effect of immunizing young children, since invasive meningococcal disease was not only reduced among vaccinees, but in all age groups.
On 22 June 2012 the Hellenic Centre for Disease Prevention and Control (KEELPNO) reported the first locally acquired case of Plasmodium vivax (P. vivax) malaria, from Marathon area in Attica region, Greece. As of 3 September, KEELPNO has reported 50 cases of malaria since the beginning of 2012 in Greece.
On 24 July 2012, the Ministry of Health of Uganda reported an outbreak of Ebola hemorrhagic fever from Kibaale district, Midwestern Uganda. As of 7 August 2012, 60 suspected cases, including 16 deaths, have been reported in Uganda.
A second case of local Plasmodium vivax malaria in Greece was reported on 17 July by KEELPNO, the Hellenic Centre for Disease Prevention and Control. The case concerned a 48 year old female resident of the municipality of Evrotas, Lakonia.
On 22 June 2012, a case of locally acquired malaria infection was reported in Greece. The case is a 78 year old Greek citizen who presumably acquired the infection close to Marathon, Attica region.
The European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC) have published their annual report on zoonoses and food-borne outbreaks in the European Union for 2010.
A meeting and a workshop on the ECDC point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use in acute care hospitals took take place in London on 5-6 March 2012.
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.